ISSN 1671-5411 CN 11-5329/R
Volume 20 Issue 10
Oct.  2023
Turn off MathJax
Article Contents
Please cite this article as: LIANG HY, LIU D, WANG H, BA ZQ, XIAO Y, LIU YL, WANG Y, YUAN JS. Pre-existing cardiometabolic comorbidities and survival of middle-aged and elderly non-small cell lung cancer patients. J Geriatr Cardiol 2023; 20(10): 737−747. DOI: 10.26599/1671-5411.2023.10.002
Citation: Please cite this article as: LIANG HY, LIU D, WANG H, BA ZQ, XIAO Y, LIU YL, WANG Y, YUAN JS. Pre-existing cardiometabolic comorbidities and survival of middle-aged and elderly non-small cell lung cancer patients. J Geriatr Cardiol 2023; 20(10): 737−747. DOI: 10.26599/1671-5411.2023.10.002

Pre-existing cardiometabolic comorbidities and survival of middle-aged and elderly non-small cell lung cancer patients

doi: 10.26599/1671-5411.2023.10.002
*The authors contributed equally to this manuscript
More Information
  •  BACKGROUND  Both lung cancer and cardiometabolic diseases are leading causes of death in China, and they share some common risk factors. However, the prevalence and long-term effect of pre-existing cardiometabolic comorbidities (CMCs) on the survival of middle-aged and elderly lung cancer patients are still not clear.  METHODS  We consecutively recruited 3477 non-small cell lung cancer (NSCLC) patients between January 2011 and December 2018 from four cancer specialty hospitals in China. Univariable and multivariable adjusted Cox proportional hazard models were conducted to evaluate the risk factors associated with mortality. Hazard ratio (HR) for mortality and corresponding 95% CI were calculated.  RESULTS  The prevalence of CMCs was 30.0% in middle-aged NSCLC patients and 45.5% in elderly NSCLC patients. Log-rank analysis presented statistically significant differences in median survival time between patients with CMCs and without CMCs in both the middle-aged group (21.0 months vs. 32.0 months, P < 0.01) and the elderly group (13.0 months vs. 17.0 months, P = 0.01). Heart failure (HR = 1.754, 95% CI: 1.436–2.144, P < 0.001) and venous thrombus embolism (HR = 2.196, 95% CI: 1.691–2.853, P < 0.001) were independent risk factors for the survival of middle-aged NSCLC patients, while heart failure (HR = 1.709, 95% CI: 1.371–2.130, P < 0.001) continued to decrease overall survival in the elderly group. Hyperlipidemia may be a protective factor for survival in middle-aged group (HR = 0.741, 95% CI: 0.566–0.971, P = 0.030).  CONCLUSIONS  Our findings demonstrate for the first time the prevalence and prognostic value of pre-existing CMCs in Chinese middle-aged and elderly NSCLC patients.
  • loading
  • [1]
    Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016; 66: 115−132. doi: 10.3322/caac.21338
    Shi JF, Wang L, Wu N, et al. Clinical characteristics and medical service utilization of lung cancer in China, 2005–2014: overall design and results from a multicenter retrospective epidemiologic survey. Lung Cancer 2019; 128: 91−100. doi: 10.1016/j.lungcan.2018.11.031
    Janssen-Heijnen ML, Smulders S, Lemmens VE, et al. Effect of comorbidity on the treatment and prognosis of elderly patients with non-small cell lung cancer. Thorax 2004; 59: 602−607. doi: 10.1136/thx.2003.018044
    Ambrogi V, Pompeo E, Elia S, et al. The impact of cardiovascular comorbidity on the outcome of surgery for stage I and II non-small-cell lung cancer. Eur J Cardiothorac Su rg 2003; 23: 811−817. doi: 10.1016/S1010-7940(03)00093-9
    Janssen-Heijnen ML, Schipper RM, Razenberg PP, et al. Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: a population-based study. Lu ng Cancer 1998; 21: 105−113. doi: 10.1016/S0169-5002(98)00039-7
    Takenaka T, Katsura M, Shikada Y, et al. The impact of cardiovascular comorbidities on the outcome of surgery for non-small-cell lung cancer. Interact Cardiovasc Thorac Su rg 2013; 16: 270−274. doi: 10.1093/icvts/ivs489
    Lüscher TF. Tumours and the heart: common risk factors, chemotherapy, and radiation. Eur Heart J 2016; 37: 2737−2738. doi: 10.1093/eurheartj/ehw451
    Sase K, Fujisaka Y, Shoji M, et al. Cardiovascular complications associated with contemporary lung cancer treatments. Curr Treat Options Oncol 2021; 22: 71. doi: 10.1007/s11864-021-00869-6
    Sturgeon KM, Deng L, Bluethmann SM, et al. A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 2019; 40: 3889−3897. doi: 10.1093/eurheartj/ehz766
    Licker M, de Perrot M, Höhn L, et al. Perioperative mortality and major cardio-pulmonary complications after lung surgery for non-small cell carcinoma. Eur J Cardioth orac Surg 1999; 15: 314−319. doi: 10.1016/S1010-7940(99)00006-8
    Liu D, Ma Z, Yang J, et al. Prevalence and prognosis significance of cardiovascular disease in cancer patients: a population-based study. Aging (Albany NY) 2019; 11: 7948−7960. doi: 10.18632/aging.102301
    Su C, Zhou F, Shen J, et al. Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced non-small cell lung cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations: still a daily challenge. Eur J Cancer 2017; 83: 266−278. doi: 10.1016/j.ejca.2017.07.002
    Caprario LC, Kent DM, Strauss GM. Effects of chemotherapy on survival of elderly patients with small-cell lung cancer: analysis of the SEER-medicare database. J Thorac Oncol 2013; 8: 1272−1281. doi: 10.1097/JTO.0b013e3182a007ba
    Borghaei H, Yim YM, Guerin A, et al. Severe adverse events impact overall survival and costs in elderly patients with advanced non-small cell lung cancer on second-line therapy. Lung Cancer 2018; 119: 112−119. doi: 10.1016/j.lungcan.2018.02.011
    Ettinger DS, Wood DE, Aisner DL, et al. NCCN guidelines insights: non-small cell lung cancer, version 2.2021. J Natl Compr Canc Netw 2021; 19: 254−266. doi: 10.6004/jnccn.2021.0013
    Herrero Rivera D, Nieto-Guerrero Gómez JM, Cacicedo Fernández de Bobadilla J, et al. Cardiovascular disease and survival in non-small cell lung cancer: a multicenter prospective assessment. Clin Transl Oncol 2019; 21: 1220−1230. doi: 10.1007/s12094-019-02047-5
    Kravchenko J, Berry M, Arbeev K, et al. Cardiovascular comorbidities and survival of lung cancer patients: medicare data based analysis. Lung Cancer 2015; 88: 85−93. doi: 10.1016/j.lungcan.2015.01.006
    Tammemagi CM, Neslund-Dudas C, Simoff M, et al. Impact of comorbidity on lung cancer survival. Int J Cancer 2003; 103: 792−802. doi: 10.1002/ijc.10882
    Banke A, Schou M, Videbaek L, et al. Incidence of cancer in patients with chronic heart failure: a long-term follow-up study. Eur J Heart Fail 2016; 18: 260−266. doi: 10.1002/ejhf.472
    Kwak S, Kwon S, Lee SY, et al. Differential risk of incident cancer in patients with heart failure: a nationwide population-based cohort study. J Cardiol 2021; 77: 231−238. doi: 10.1016/j.jjcc.2020.07.026
    Hasin T, Gerber Y, Weston SA, et al. Heart failure after myocardial infarction is associated with increased risk of cancer. J Am Coll Cardiol 2016; 68: 265−271. doi: 10.1016/j.jacc.2016.04.053
    Miller KD, Siegel RL, Lin CC, et al. Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 2016; 66: 271−289. doi: 10.3322/caac.21349
    Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710−717. doi: 10.7326/0003-4819-91-5-710
    Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 2003; 97: 2869−2879. doi: 10.1002/cncr.11407
    D’Souza M, Nielsen D, Svane IM, et al. The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study. Eur Heart J 2021; 42: 1621−1631. doi: 10.1093/eurheartj/ehaa884
    Anker MS, Coats AJS, Anker SD. Cardiac events associated with immune checkpoint inhibitor therapy: the devil is in the detail. Eur Heart J 2021; 42: 1637. doi: 10.1093/eurheartj/ehab063
    Corrales-Rodriguez L, Blais N. Lung cancer associated venous thromboembolic disease: a comprehensive review. Lung Cancer 2012; 75: 1−8. doi: 10.1016/j.lungcan.2011.07.004
    Su Y, Huo M, Hua L, et al. Association of venous thromboembolism and early mortality in patients with newly diagnosed metastatic non-small cell lung cancer. Cancer Ma nag Res 2021; 13: 4031−4040. doi: 10.2147/CMAR.S301088
    Hill H, Robinson M, Lu L, et al. Venous thromboembolism incidence and risk factors in non-small cell lung cancer patients receiving first-line systemic therapy. Thromb Res 2021; 208: 71−78. doi: 10.1016/j.thromres.2021.10.014
    Lee YG, Kim I, Lee E, et al. Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer. Thromb Haemost 2014; 111: 1112−1120. doi: 10.1160/TH13-11-0956
    Chew HK, Davies AM, Wun T, et al. The incidence of venous thromboembolism among patients with primary lung cancer. J Thromb Haemost 2008; 6: 601−608. doi: 10.1111/j.1538-7836.2008.02908.x
    Nalluri SR, Chu D, Keresztes R, et al. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA 2008; 300: 2277−2285. doi: 10.1001/jama.2008.656
    Crinò L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small-cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010; 11: 733−740. doi: 10.1016/S1470-2045(10)70151-0
    Zhang Y, Xu J, Lou Y, et al. Pretreatment direct bilirubin and total cholesterol are significant predictors of overall survival in advanced non-small-cell lung cancer patients with EGFR mutations. Int J Cancer 2017; 140: 1645−1652. doi: 10.1002/ijc.30581
    Sok M, Ravnik J, Ravnik M. Preoperative total serum cholesterol as a prognostic factor for survival in patients with resectable non-small-cell lung cancer. Wien Klin Wochen schr 2009; 121: 314−317. doi: 10.1007/s00508-009-1169-8
    Li JR, Zhang Y, Zheng JL. Decreased pretreatment serum cholesterol level is related with poor prognosis in resectable non-small cell lung cancer. Int J Clin Exp Pathol 2015; 8: 11877−11883.
    Chi PD, Liu W, Chen H, et al. High-density lipoprotein cholesterol is a favorable prognostic factor and negatively correlated with C-reactive protein level in non-small cell lung carcinoma. PLoS One 2014; 9: e91080. doi: 10.1371/journal.pone.0091080
    Lv Y, Miao LY, Chen QF, et al. Monitoring of high-density lipoprotein cholesterol level is predictive of EGFR mutation and efficacy of EGFR-TKI in patients with advanced lung adenocarcinoma. Onco Targets Ther 2016; 9: 461−468. doi: 10.2147/OTT.S96199
    Ma C, Wang X, Guo J, et al. Prognostic significance of preoperative serum triglycerides and high-density lipoproteins cholesterol in patients with non-small cell lung cancer: a retrospective study. Lipids Health Dis 2021; 20: 69. doi: 10.1186/s12944-021-01492-y
    Baracos VE, Martin L, Korc M, et al. Cancer-associated cachexia. Nat Rev Dis Primers 2018; 4: 17105. doi: 10.1038/nrdp.2017.105
    Irwin ME, Mueller KL, Bohin N, et al. Lipid raft localization of EGFR alters the response of cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol 2011; 226: 2316−2328. doi: 10.1002/jcp.22570
    Hao B, Yu M, Sang C, et al. Dyslipidemia and non-small cell lung cancer risk in Chinese population: a case-control study. Lipids Health Dis 2018; 17: 278. doi: 10.1186/s12944-018-0925-z
    Li R, Liu B, Liu Y, et al. Elevated serum lipid level can serve as early signal for metastasis for non-small cell lung cancer patients: a retrospective nested case-control study. J Cancer 2020; 11: 7023−7031. doi: 10.7150/jca.48322
    YuPeng L, YuXue Z, PengFei L, et al. Cholesterol levels in blood and the risk of prostate cancer: a meta-analysis of 14 prospective studies. Cancer Epidemiol Biomarkers Prev 2015; 24: 1086−1093. doi: 10.1158/1055-9965.EPI-14-1329
    Fang Z, He M, Song M. Serum lipid profiles and risk of colorectal cancer: a prospective cohort study in the UK Biobank. Br J Cancer 2021; 124: 663−670. doi: 10.1038/s41416-020-01143-6
    Beeghly-Fadiel A, Khankari NK, Delahanty RJ, et al. A Mendelian randomization analysis of circulating lipid traits and breast cancer risk. Int J Epidemiol 2020; 49: 1117−1131. doi: 10.1093/ije/dyz242
    Johnson KE, Siewert KM, Klarin D, et al. The relationship between circulating lipids and breast cancer risk: a Mendelian randomization study. PLoS Med 2020; 17: e1003302. doi: 10.1371/journal.pmed.1003302
  • 加载中


    通讯作者: 陈斌,
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(2)  / Tables(4)

    Article Metrics

    Article views (103) PDF downloads(17) Cited by()
    Proportional views


    DownLoad:  Full-Size Img  PowerPoint